BeOne Medicines (ONC) Cash from Investing Activities (2015 - 2026)

BeOne Medicines (ONC) has reported Cash from Investing Activities for 12 consecutive years, with -$45.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 62.68% year-over-year to -$45.5 million; the TTM figure through Mar 2026 stood at -$199.7 million (up 56.63% YoY), while the FY2025 annual figure was -$276.2 million, up 49.64% from the prior year.
• Cash from Investing Activities retreated to -$45.5 million in Q1 2026 per ONC's latest filing, from -$38.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $658.7 million in Q2 2022 and bottomed at -$209.8 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged $15.7 million across 5 years, with a median of -$49.3 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 1512.96% — and 2024, when it tumbled 263.76%.
• BeOne Medicines' Cash from Investing Activities stood at $38.5 million in 2022, then slumped by 262.4% to -$62.6 million in 2023, then tumbled by 49.57% to -$93.6 million in 2024, then surged by 59.05% to -$38.3 million in 2025, then decreased by 18.72% to -$45.5 million in 2026.
• Business Quant data shows ONC's Cash from Investing Activities at -$45.5 million in Q1 2026, -$38.3 million in Q4 2025, and -$49.3 million in Q3 2025.